I think the Robo will be ok too btw. It might nip at $57 again, no biggie though.
Oh geeze thanks. These snooty SNAP owners....
Oh geeze thanks. These snooty SNAP owners....
GBA Presents: THE GREEN MARKET
- Thread starter stonedinvestor
- Start date
GitLab Inc. (GTLB)
66.93+5.32 (+8.63%)
As of 12:22PM EST.
66.93+5.32 (+8.63%)
As of 12:22PM EST.
eBay Inc. (EBAY)
59.21+2.02 (+3.53%)
As of 12:23PM EST.
59.21+2.02 (+3.53%)
As of 12:23PM EST.
Closing out. Taking approx $5 trade
Sprout Social, Inc. (SPT)-
66.02+5.06 (+8.30%)
As of 12:24PM EST. Market open.
Robo +3%
Dept. of Justice said to probe almost 30 short selling firms, allies
Feb. 04, 2022 11:50 AM ET
The U.S. Dept of Justice is said to be collecting information on dozens of investment firms and researches involved in short selling as part of an investigation in possible trading violations.
The DOJ has subpoenaed communications and other info from almost 30 investment and research firms, according to traders, who cited a Bloomberg report. No one has been accused of wrongdoing and the opening of the investigation doesn't mean individuals will face any charges.
The report comes after Bloomberg in December reported that DOJ was said to have started a criminal probe into short selling by hedge funds and research firms looking at potentially improperly coordinated trades and insider trading.
The agency seized computers from well known short seller Andrew Left of Citron Research early last year, according to the latest report. Left told Bloomberg he's cooperating, though he added "it’s very tough to defend yourself when you haven’t been accused of anything.”
News about the probe in December hasn't stopped shorts from releasing reports as evidenced by at least four short reports that came out Thursday including prominent short seller Hindenburg Research on Standard Lithium (NYSE:SLI) and Grizzly Research on Playtika (NASDAQ:PLTK).
Feb. 04, 2022 11:50 AM ET
The U.S. Dept of Justice is said to be collecting information on dozens of investment firms and researches involved in short selling as part of an investigation in possible trading violations.
The DOJ has subpoenaed communications and other info from almost 30 investment and research firms, according to traders, who cited a Bloomberg report. No one has been accused of wrongdoing and the opening of the investigation doesn't mean individuals will face any charges.
The report comes after Bloomberg in December reported that DOJ was said to have started a criminal probe into short selling by hedge funds and research firms looking at potentially improperly coordinated trades and insider trading.
The agency seized computers from well known short seller Andrew Left of Citron Research early last year, according to the latest report. Left told Bloomberg he's cooperating, though he added "it’s very tough to defend yourself when you haven’t been accused of anything.”
News about the probe in December hasn't stopped shorts from releasing reports as evidenced by at least four short reports that came out Thursday including prominent short seller Hindenburg Research on Standard Lithium (NYSE:SLI) and Grizzly Research on Playtika (NASDAQ:PLTK).
Should we warn granny?Dept. of Justice said to probe almost 30 short selling firms, allies
Feb. 04, 2022 11:50 AM ET
The U.S. Dept of Justice is said to be collecting information on dozens of investment firms and researches involved in short selling as part of an investigation in possible trading violations.
The DOJ has subpoenaed communications and other info from almost 30 investment and research firms, according to traders, who cited a Bloomberg report. No one has been accused of wrongdoing and the opening of the investigation doesn't mean individuals will face any charges.
The report comes after Bloomberg in December reported that DOJ was said to have started a criminal probe into short selling by hedge funds and research firms looking at potentially improperly coordinated trades and insider trading.
The agency seized computers from well known short seller Andrew Left of Citron Research early last year, according to the latest report. Left told Bloomberg he's cooperating, though he added "it’s very tough to defend yourself when you haven’t been accused of anything.”
News about the probe in December hasn't stopped shorts from releasing reports as evidenced by at least four short reports that came out Thursday including prominent short seller Hindenburg Research on Standard Lithium (NYSE:SLI) and Grizzly Research on Playtika (NASDAQ:PLTK).
Hey btw... Yulia says Roblox is all the rage amongst her friends with kids.
I think it's stupid myself. I'm not surprised however.
Van you have ruined my day. Everything I look up has this SNAP next to it.....
This is how The Savant works... I look up Yahoo finance and I stare and I say whatever happened to Iovance IOVA and I check and
Iovance Biotherapeutics to Present Data on Tumor-Infiltrating Lymphocyte (TIL) Cell Therapy at the 2022 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR®
Iovance Biotherapeutics Inc
January 7, 2022
TIL Therapy was Successfully and Consistently Manufactured from Cryopreserved Tumor Samples Shipped from Australia
Local Cryopreservation of Tumor Samples may Address Challenges of Longer Shipment Times and Broaden Global Access for TIL Therapy
SAN CARLOS, Calif., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will present data on Iovance tumor-infiltrating lymphocyte (TIL) cell therapy at the upcomingTandem Meetings| Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR®, to be held February 2 – 6, 2022 in Salt Lake City, Utah, and virtually.
Today is Feb 4.........
About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics aims to be the global leader in innovating, developing and delivering tumor infiltrating lymphocyte (TIL) cell therapies for patients with cancer. We are pioneering a transformational approach to cure cancer by harnessing the human immune system’s ability to recognize and destroy diverse cancer cells in each patient. Our lead late-stage TIL product candidate, lifileucel for metastatic melanoma, has the potential to become the first approved one-time cell therapy for a solid tumor cancer. The Iovance TIL platform has demonstrated promising clinical data across multiple solid tumors. We are committed to continuous innovation in cell therapy, including gene-edited cell therapy, that may extend and improve life for patients with cancer.
I quite like this co. Sector has been in the dog house....
This is how The Savant works... I look up Yahoo finance and I stare and I say whatever happened to Iovance IOVA and I check and
Iovance Biotherapeutics to Present Data on Tumor-Infiltrating Lymphocyte (TIL) Cell Therapy at the 2022 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR®
Iovance Biotherapeutics Inc
January 7, 2022
TIL Therapy was Successfully and Consistently Manufactured from Cryopreserved Tumor Samples Shipped from Australia
Local Cryopreservation of Tumor Samples may Address Challenges of Longer Shipment Times and Broaden Global Access for TIL Therapy
SAN CARLOS, Calif., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will present data on Iovance tumor-infiltrating lymphocyte (TIL) cell therapy at the upcomingTandem Meetings| Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR®, to be held February 2 – 6, 2022 in Salt Lake City, Utah, and virtually.
Today is Feb 4.........
About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics aims to be the global leader in innovating, developing and delivering tumor infiltrating lymphocyte (TIL) cell therapies for patients with cancer. We are pioneering a transformational approach to cure cancer by harnessing the human immune system’s ability to recognize and destroy diverse cancer cells in each patient. Our lead late-stage TIL product candidate, lifileucel for metastatic melanoma, has the potential to become the first approved one-time cell therapy for a solid tumor cancer. The Iovance TIL platform has demonstrated promising clinical data across multiple solid tumors. We are committed to continuous innovation in cell therapy, including gene-edited cell therapy, that may extend and improve life for patients with cancer.
I quite like this co. Sector has been in the dog house....
Watch:
IOVA
Iovance Biotherapeutics
IOVA
Iovance Biotherapeutics